Xeris Biopharma Holdings, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:XERS) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Total assets 392.01 M334.69 M370.19 M383.53 M411.9 M Total liabilities 379 M353.99 M371.05 M369.84 M421.64 M Total equity 13.01 M-19.3 M-861 K13.69 M-9.73 M Total liabilities & shareholders' equities 392.01 M334.69 M370.19 M383.53 M411.9 M Total debt 221.22 M218.63 M219.47 M220.34 M252.59 M Net debt 109.47 M218.63 M127.87 M109.29 M130.84 M

News

Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity (XERS)

Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?

Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right (NASDAQ:XERS)

Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Xeris Pharmaceuticals at Barclays: Strong Growth Fueled by RECORLEV

Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say

Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates

Xeris Biopharma stock up nearly 3% after Q4 EPS beat, above estimate guidance

Xeris Pharmaceuticals earnings beat by $0.04, revenue topped estimates